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COriginal articleMetabolomic does not predict response to cardiac
resynchronization therapy in patients with heart failure
Luigi Padelettia,b, Pietro A. Modestia, Stella Carteia, Luca Checchia,
Giuseppe Ricciardia, Paolo Pieragnolia, Stefania Sacchia,
Margherita Padelettic, Brunetto Alterinia, Pietro Pantaleoa, Xiaoyu Hud,
Leonardo Tenorid,e and Claudio Luchinate,fAims Metabolomic, a systematic study of metabolites, may
be a useful tool in understanding the pathological
processes that underlie the occurrence and progression of
a disease. We hypothesized that metabolomic would be
helpful in assessing a specific pattern in heart failure
patients, also according to the underlining causes and in
defining, prior to device implantation, the responder and
nonresponder patient to cardiac resynchronization therapy
(CRT).
Methods In this prospective study, blood and urine samples
were collected from32 heart failure patients who underwent
CRT. Clinical, electrocardiography and echocardiographic
evaluation was performed in each patient before CRT and
after 6 months of follow-up. Thirty-nine age and sex-
matched healthy individuals were chosen as control group.
For each sample, 1H-NMR spectra, Nuclear Overhauser
Enhancement Spectroscopy, Carr-Purcell-Meiboom-Gill
and diffusion edited spectra were measured.
Results A different metabolomic fingerprint was
demonstrated in heart failure patients compared to healthy
controls with high accuracy level. Metabolomics fingerprint
was similar between patients with ischemic and
nonischemic dilated cardiomyopathy. At 6-month follow-up,
metabolomic fingerprint was different from baseline. Atopyright © Italian Federation of Cardiology. Una
1558-2027  2014 Italian Federation of Cardiologyfollow-up, heart failure patients’ metabolomic fingerprint
remained significantly different from that of healthy
controls, and accuracy of cause discrimination remained
low. Responders and nonresponders had a similar
metabolic fingerprint at baseline and after 6 months
of CRT.
Conclusion It is possible to identify a metabolomic
fingerprint characterizing heart failure patients
candidate to CRT, it is independent of the different causes
of the disease and it is not predictive of the response to
CRT.J Cardiovasc Med 2014, 15:295–300
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Metabolomic is the systematic study of small-molecule
metabolites that are by-products of cellular metabolism.
The metabolomic fingerprint, derived from specific
protein enzymatic processes, directly correlates with
the clinical phenotype of the diseases.1–3 Cardiac resyn-
chronization therapy (CRT) has shown a clear clinical
benefit in heart failure patients by improving symptoms,
quality of life, exercise capacity and cardiac function,
significantly reducing morbidity and mortality,4–9 but up
to 40% of heart failure patients are nonresponder to
CRT.10,11 As an emerging discipline for molecular profil-
ing, metabolomic may increase understanding of human
diseases and clinical risk because changes in metabolite
levels provide a real-time estimate of disease state and
reflect the integrated effects of genomic, transcriptomic
and proteomic variation.3 The purpose of this prospectivestudy was to assess if there is a specific metabolic profile
in heart failure patients compared to healthy individuals;
to investigate whether there is a difference in metabolic
profile between patients with ischemic and nonischemic
dilated cardiomyopathy; and, finally, to assess if there is a
different metabolic pattern at baseline and at follow-up in
responders and nonresponders to CRT.
Methods
Study population
Patients with ischemic and nonischemic dilated cardio-
myopathy who underwent implantation of CRT at our
institute were enrolled in the study. Dilated cardiomyo-
pathy was diagnosed based on clinical history, echocar-
diographic examination, cardiac catheterization, and
coronary angiography. Inclusion criteria were 6 months
of optimal medical therapy, New York Heart Associationuthorized reproduction of this article is prohibited.
DOI:10.2459/JCM.0000000000000028
Co
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tion fraction (LVEF) 35% or less. Exclusion criteria
were end-stage renal disease, clinical and hemodynamic
instability, and tumor with a life expectancy of less than
1 year. Thirty-nine healthy blood donors were used as
control. The study conforms to the principles outlined in
the Declaration of Helsinki. The institutional review
board approved the protocol and all patients gave written
informed consent.
Study protocol
All patients underwent clinical and physical examination:
NYHA functional class, ECG, echocardiogram with tis-
sue Doppler imaging (TDI), Short Form-36 question-
naire of quality of life were assessed.12 Peripheral blood
and urine sample were collected at baseline, before pace-
maker implantation, and after 6 months of CRT. Thirty-
one patients had biventricular defibrillator (CRT-D
device); only one patient had a biventricular pacemaker
(CRT-P device). All patients were implanted through
cephalic or subclavian left vein into right atrium, apex of
right ventricle and into the coronary sinus to pace left
ventricle lateral wall. Biventricular pacing parameters
were optimized 1 week after implantation on the basis
of the myocardial performance index (MPI), calculated as
the sum of isovolumic contraction and relaxation times
divided by ejection time. Optimum atrioventricular delay
and interventricular delay were identified by the mini-
mumMPI in each patient.13 Echocardiographic measure-
ments were repeated at 6-month follow-up. CRT
responders at the 6-month follow-up were defined as
those with a reduction of left-ventricular end-systolic
volume (LVESV) more than 15%; patients were defined
as nonresponders if LVESV at follow-up remained
unchanged or was reduced by less than 15% compared
with baseline.13–16
Blood and urine samples management
Venous blood samples from heart failure patients and
controls were collected into plastic tubes (BDVacutainer,
Franklin Lakes, New Jersey, USA). Serum samples were
then centrifuged at 48C at 5000 r.p.m. for 15min. Aliquots
of 400ml were finally transferred in cryovial (Bruker
BioSpin, Milan, Italy), frozen and stored at 808C until
used. Freshly voided urine samples from heart failure
patients were centrifuged at 48C at 5000 r.p.m. for 15min.
Aliquots of 800ml were transferred in cryovial, immedi-
ately frozen and stored at 808C until used.
NMR samples preparation
Frozen serum and urine samples were thawed at room
temperature and shaken. Three-hundred microliter of
sodium phosphate buffer was added to equal quantity of
serum sample, and 450ml of this mixture was pipetted
into a 4.25-mm NMR tube (Bruker BioSpin) for analysis.
Seventymicroliter of sodium phosphate buffer was added
to 630ml of urine. Samples were centrifuged at 1.4 104gpyright © Italian Federation of Cardiology. Unaufor 5min and 600ml supernatant was transferred into
4.25-mm NMR tubes (Bruker BioSpin).
NMR analysis and spectral processing
One-dimensional 1H-NMR spectra were measured on a
Bruker 600MHz spectrometer using standardized proto-
cols. Nuclear Overhauser Enhancement Spectroscopy
(1D-NOESY)17 spectra were acquired for serum and urine
samples; Carr-Purcell-Meiboom-Gill (1D-CPMG)18 and
diffusion edited (DIFF)19 spectra were acquired for serum
samples only. 1D-CPMG spectra contain signals arising
mostly from low-molecular-mass metabolites, DIFF
spectra contain signals arising mostly from macro-
molecules, whereas 1D-NOESY spectra contain both
kinds of signals. Each spectrum in the region 10.00–
0.02 ppm (excluding thewater region) was segmented into
416 0.02-ppm chemical shift bins (buckets) prior to any
statistical analysis. Bucketing is a means to reduce the
number of total variables and to compensate for small shifts
in the signals. Serum spectra were not normalized,20
whereas urine spectra were normalized to the total
area intensity.
Statistical analysis
Continuous variables were expressed as mean  SD.
Continue variables were analyzed with the Student’s
t-test and one-way analysis of variance (ANOVA), when
appropriate.
The statistical procedure employed for classification is
the orthogonal partial least squares discriminant analysis
(OPLS-DA).21 OPLS is a newly developed variant of
partial least squares (PLS) analysis. Briefly, it is a pro-
jection technique aimed at building a discrimination
space (obtained by linear combinations of the original
predictors) where the groups of interest are maximally
divided. Predictive and uncorrelated information is kept
separated in the model. After the training model is build,
new samples can be predicted by projecting it in the
discriminant space. This was done in Fig. 2 to assess
whether follow-up samples are more similar to baseline
samples or to controls. The accuracy for classification
was assessed by means of a double cross-validation
scheme.22,23 The original data set was split into a training
set (80%) and a test set (20%) randomly before any step of
statistical analysis. The number of OPLS components
(3–40 components) was chosen on the basis of a five-fold
cross-validation performed on the training set only, and
the best model was used to predict the samples in the test
set. The whole procedure was repeated 200 times with a
Monte Carlo cross-validation scheme, and the results
averaged. To assess the significant differences of metab-
olites (i.e. NMR peaks) from different groups, a univari-
ate Wilcoxon test was used. A total of 41 NMR peaks for
serum and 29 for urine spectra were tested. A P-value of
0.05 or less (not corrected for multiple test) was con-
sidered statistically significant. Two kinds of comparisonsthorized reproduction of this article is prohibited.
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(b)were performed: the comparison between patients and
healthy controls (32 vs. 39 samples) and the comparison
between baseline patients and 6-month follow-up
patients (32 vs. 32 samples). Following the Cohen for-
mulation of power calculation, and using a t-test as
model, these numbers were sufficient, in the first case,
to detect moderate effects (d¼ 0.7) at a significance level
of 0.05 with a statistical power higher than 0.8. For the
second analysis, because the patients were the same
before and after follow-up, and so the test was paired,
the statistical power was higher than 0.95, at the same
significance level and assuming the same moderate
effect. Alternatively, this means that we can detect even
smaller effects (d¼ 0.5) still with a sufficient power
(0.82).
We avoided the use of Bonferroni correction because of
the rise of the risk of false-negatives; anyway metabolites
still statistically significant (P 0.001 for serum and
P 0.002 for urines) after this correction were also
reported.
All resonances of interest were then manually checked,
and signals were assigned on template one-dimensional
NMR profiles by using matching routines of AMIX 3.8.4
(Bruker BioSpin) in combination with the BBIOREF-
CODE (Version 2-0-0; Bruker BioSpin) reference data-
base24 and published literature when available. All
calculations for metabolomic purpose analysis were made
using home-made scripts written in our lab using the
R language.25opyright © Italian Federation of Cardiology. Unauthorized reproduction of this article is prohibited.
Table 1 Demographic and clinical characteristics of the studied
population values are reported as number, percentage or medianW
SD
Controls HF patients (baseline)
Sex (W/M) 11/28 9/23
Age (years) 68.71.9 70.712.5
Weight (kg) 78.111.7 78.817.7
HF cause, ischemic (n) – 12
NYHA class (II/III/IV) (n) – 11/16/5
LVEF (%) > 55 296
QRS duration (ms) < 120 14236
SBP (mmHg) 13316 12418
Laboratory:
Hemoglobin (g/dl) 14.80.9 12.61.8
Leucocytes (103/ml) 6.01.2 7.42.7
Cholesterol, total (mg/dl) 21029 15439
Cholesterol, LDL (mg/dl) 13819 90.731.2
Triglycerides (mg/dl) 10840 11853
Glucose (g/dl) 0.870.2 0.950.18
Creatinine (mg/dl) 0.850.17 1.140.58
sMDRD (ml/min) 9619 7427
Medications
ACE-I (n) – 17
ARB (n) – 11
b-blockers (n) – 27
Aldosterone antagonists (n) – 11
Diuretics (n) – 28
Allopurinol (n) – 5
Statins (n) – 19
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; HF, heart failure; LDL, low-density lipoprotein; LVEF, left-ventricular
ejection fraction; M, men; NYHA, New York Heart Association; sMDRD, simplified
modification of diet in renal disease; W, women.
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(c)
Descriptive clustering of heart failure patients at baseline (black
dots) and controls (red dots) obtained by use of OPLS method on
serum NOESY (a), CPMG (b) and DIFF spectra. CPMG, Carr-
Purcell-Meiboom-Gill; DIFF, diffusion edited; NOESY, Nuclear
Overhauser Enhancement Spectroscopy; OPLS, orthogonal partial
least squares.
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Study population
Between October 2010 and October 2012, 32 patients
(23 men, nine women) who underwent implantation of
CRT were enrolled. During follow-up, two patients died
because of heart failure complications. Baseline demo-
graphic and clinical characteristics are listed in Table 1.
No significant difference was found between controls and
patients in terms of age and sex.
Molecular signatures at baseline
A different metabolomic fingerprint was demonstrated in
serum of heart failure patients compared to healthy
controls with high accuracy level (NOESY: 93.3%;
CPMG: 99.1%; DIFF: 95.7%), as shown in Fig. 1. Heart
failure patients were characterized by significantly lower
levels of lactate, methionine and higher levels of formate,
phenylalanine, glucose, serine, acetate, dimethylsulfone,
hypoxanthine, creatinine þ creatine, and trimethyla-
mine-N-oxide compared to healthy controls (Table 2).
No significant difference was demonstrated between
ischemic and nonischemic patients before CRT. The
accuracy of cause discrimination at baseline was only
63.4% for NOESY, 59.2% for CPMG, and 59.4% for
DIFF serum spectra. Cause discrimination remained
low when considering urine spectra (58.2% for NOESY).
Molecular signatures at 6 months follow-up
After 6 months of CRT, OPLS analysis showed that none
of the patients had a metabolomic fingerprint in the area
of healthy controls (Fig. 2). Likewise, the accuracy of
discrimination between heart failure causes remained low
both for serum (64.6% for NOESY, 61.1% for CPMG and
62.5% for DIFF) and urine spectra (65.3%for NOESY).
Pair-wise multivariate statistics indicated that metabo-
lomic fingerprint at this time could be discriminated from
those at baseline with suboptimal accuracy both for serum
(71.8% for NOESY, 81.4% for CPMG and 72.6% for
DIFF) and urine spectra (70.1% for NOESY). Serum
spectra revealed a significant increase of tyrosine, lactate,
proline, alanine and lipid (–CH¼CH–) (Table 3). In
urine spectra, the levels of hippurate and trigonellinepyright © Italian Federation of Cardiology. Unau
Table 2 Metabolites found to be statistically different in serum of HF
Serum metabolites
CHF
Mean 95% CI
Formate 10.11 3.81–15.25
Phenylalanine 156.91 97.49–239.16
Glucose 2419.9 1768.1–3634.5
Lactate 1609.3 662.24–3476.95
Serine 622.16 460.05–813.67
Acetate 309.69 214.89–492.73
Methionine 12.97 0.01–75.55
Dimethylsulfone 71.37 31.88–151.89
Hypoxanthine 15.91 4.33–38.08
Trimethylamine-N-oxide 83.97 5.62–288.74
Creatinine þ creatine 418.88 249.98–669.61
CI, confidence interval; HF, heart failure. a Values are given in arbitrary units togethe
(P0.001).were reduced, whereas threonine levels were increased
when compared to baseline (Table 3). Echocardiographic
criteria allowed identifying 19 responder and 11 non-
responder patients.No significant differencewas observed
in responders’ metabolomic fingerprint with respect to
nonresponders at baseline (accuracy levels: 45.2% for
NOESY spectra, 46.7% for CPMG spectra, 50.8% for
DIFF spectra; 43.7% for urine NOESY spectra) and after
6 months follow-up (accuracy levels: 35.3% for NOESY
spectra, 32.1% forCPMGspectra, 35.7% forDIFF spectra;
44.5% for urine NOESY spectra).
Discussion
In this study, we demonstrated the existence of a specific
metabolomic fingerprint that characterizes patients with
dilated cardiomyopathy candidate to CRT compared with
healthy individuals. Metabolomic fingerprint of heart
failure patients resulted to be characterizedby lower levels
of lactate, methionine and by higher levels of formate,
phenylalanine, glucose, serine, acetate, dimethylsulfone,
hypoxantine, creatine þ creatinine, and trimethylamine-
N-oxide (Table 2). Other authors have shown a specific
metabolomic fingerprint in heart failure patients. In the
study by Lin et al.,26 who used the same techniques as our
study, the metabolomic fingerprint was characterized by
higher levels of acetoacetate and urea and by lower levels
of threonine, glycine, ethanol, histidine, alanine and tyro-
sine, results which were significantly different from our
heart failure patient population. In the study by Dunn
et al.,27 who employed gas chromatography and mass
spectrometry, pseudopurine and 2-oxoglutarate were
identified as two good indicators of heart failure. These
metaboliteswere different from those reportedbyLin et al.
and in our studies. These results could be due to the
different characteristics of patients investigated (Lin
et al.26 analyzed end-stage heart failure patients just before
transplantation) or to the different samples analysis tech-
nique performed (Dunn et al.27 used gas chromatography).
It is possible to affirm thatmetabolomic approach is able to
identify a fingerprint characterizing heart failure patients,
but a univocal and reproducible pattern is still not emerged
in the literature.thorized reproduction of this article is prohibited.
patients at baseline with respect to the control groupa
Healthy control
P-valueMean 95% CI
8.99 4.64–19.12 0.014
132.69 112.42–164.35 0.005
2142.5 1759.1–2984.2 0.022
1893.65 1055.9–2857.3 0.019
510.54 421.79–627.49 7.7e-7

252.76 198.82–318.37 0.02
52.42 0.02–264.96 4.4e-6

54.74 16.78–150.04 0.002
8.58 0.02–16.51 8.4e-5

31.09 2.85–66.94 2.9e-4

309.77 242.26–422.88 3.37e-5

r with confidence intervals at 95%.

Still significant after Bonferroni correction
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Predictive analysis of serum CPMG spectra of patients after 6 months of CRT. Follow-up spectra are projected on the discriminant model built on the
39 controls’ and 32 baseline patients’ spectra. CPMG, Carr-Purcell-Meiboom-Gill; CRT, cardiac resynchronization therapy; OPLS, orthogonal partial
least squares.This poor reproducibility of the result impairs the validity
of themethod. Similar to the study byLin et al.26, we could
not assess a different metabolic pattern in patients with
different ischemic and nonischemic cardiomyopathy at
baseline and after 6 months of CRT. This implies the
existence of a common final pathway irrespective of the
cause of the dilated cardiomyopathy. Therefore, metabo-
lomic approach is not helpful in improving the diagnostic
process necessary to define the cause of heart failure.
After 6 months of CRT, we observed a totally different
metabolic pattern from baseline, which resulted to be
further different from the fingerprint of healthy controls.
In none of the patients, metabolomic fingerprint returned
in the area of healthy controls at 6 months of follow upopyright © Italian Federation of Cardiology. Una
Table 3 Metabolites found to be statistically different in serum and urin
CHF before CRT
Mean 95% CI
Serum metabolites
Tyrosine 138.72 103.63–193.02
Lactate 1640.77 662.24–3476.95
Proline 531.03 268.35–797.93
Alanine 1141.17 722.22–1751.14
Lipid (-CH¼CH-) 8554.31 4924.54–14253.7
Urine metabolites
Hippurate 0.011 0.002–0.026
Trigonelline 0.0023 0.0002–0.0044
Threonine 0.0018 0.001–0.0033
CI, confidence interval; CRT, cardiac resynchronization therapy; HF, heart failure. a Va
significant after Bonferroni correction (P0.002).(Fig. 2). Analyzing samples obtained at this time, we
identified another specific pattern, even if with a subopti-
mal level of accuracy (above 70%). The levels of serum
metabolites – tyrosine, lactate, proline, alanine and lipid
(–CH¼CH–) – were significantly higher when compared
to baseline (Table 3); similarly, at 6 months of follow up,
results showed that urine metabolite levels of hippurate
andtrigonelline were significantly lower, whereas levels of
threonine were significantly higher (Table 3). These
differences in metabolomic spectra could be considered
as the expression of complex cellular andmolecular modi-
fication induced by CRT. In fact, as Chakir and Kass28
have observed, CRT can get the failing heart to contract
more and perform more work, improving ion channel
function involvedwith electrical repolarization, enhancinguthorized reproduction of this article is prohibited.
e of HF patients at the 6-month follow-up with respect to baselinea
CHF 6 months after CRT
P-valueMean 95% CI
161.57 112.46–216.55 0.002
2602.43 1125.55–4871.36 0.002
603.41 374.91–980.81 0.04
1336.38 848.19–1999.55 0.02
9743.96 5575.39–21072.9 0.03
0.019 0.007–0.069 0.01
0.0028 0.0009–0.0053 0.04
0.0013 0.0008–0.0019 0.001

lues are given in arbitrary units together with confidence intervals at 95%.

Still
Co
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up-regulation of beta-adrenergic responses and improving
mitochondrial energetic efficiency.
According to the present literature, up to 40% of patients
may not experience any improvement in clinical status
and/or reversal of cardiac remodeling after CRT.29 An
increase in LVEF above 7.5% during low-dose dobuta-
mine echocardiography exhibited a sensitivity of 76% and
a specificity of 86% in predicting response to CRT.30 The
burden and the transmural extension of myocardial scar
measured by cardiovascular MRI have been shown to be
associated with a poor response rate to CRT,31 similar to a
high scar burden quantified by single photon emission
computed tomography myocardial perfusion imaging.32
Other clinical, electromechanical and electrophysio-
logical issues before device implantation have been
identified by Mullens et al.29 In the present study, we
demonstrated that metabolomic is unable to predict the
outcome of CRT patients: NOESY, CPMG and DIFF
spectra for both serum and urine samples showed very
low discrimination accuracy (from 43.7 to 50.8%) that
precludes its use in common clinical practice.
Conclusion
Although it is possible to identify a metabolomic finger-
print that characterizes heart failure patients candidate to
CRT, this pattern is quite different in different studies
and is unaffected by the different causes of the disease.
Furthermore, this approach seems unable to identify a
metabolic profile predictive of a favorable response to
CRT. Therefore, at the current state of the art, the use of
this method is not justified in patients undergoing CRT.
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